A participant in Oxford vaccine trial, Dr Jasmeet Bindra revealed that University of Oxford’s experimental COVID-19 vaccine might be available in September.
Dr Jasmeet Bindra, who is a consultant psychiatrist in UK’s Scotland, had volunteered for Phase III group of coronavirus vaccine trial conducted by Oxford University.
Talking to TV Punjab’s senior journalist Davi Davinder Kaur, Dr Bindra told that the phase III part of the study involves assessing how the vaccine works in a large number of people between the age group of 18 to 55. Participants are randomised to receive one or two doses of either the ChAdOx1 nCoV-19 vaccine or a licensed vaccine (MenACWY) that will be used as a ‘control’ for comparison.
“Participants will not know whether they have received the ChAdOx1 nCoV-19 vaccine until the end of the trial,” said Dr Jasmeet.
ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans. It will generate a good immune response to the spike protein that will help stop the virus from entering the human body.
The MenACWY vaccine is a licensed vaccine against group A, C, W and Y meningococcus which has been given routinely to teenagers in the UK since 2015 and protects against one of the most common causes of meningitis and sepsis. This vaccine is also given as a travel vaccine for high risk countries.
“It’s possible that there would be vaccines available by the end of the year,” said UK-based Punjabi psychiatrist, Dr Jasmeet.